A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer

Graham DM, Isaranuwatchai W, Habbous S, et al. Cancer. Published Online First: 13 April 2015. doi:10.1002/cncr.29111 The human papillomavirus (HPV) is an oncogenic virus associated with anogenital and head and neck cancers in both sexes. HPV vaccination has already been introduced in the national immunisation programmes of 63 countries to prevent cervical cancer;1 however, few countries are recommending HPV vaccination for male patients. There are limited published data on the benefit of male HPV vaccination in preventing extra-genital HPV-related cancers. Furthermore, the efficacy of HPV vaccination in preventing oropharyngeal carcinoma (OPC) is as yet undemonstrated due to a …